English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
康哲藥業(867.HK;8A8.SG)長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理
Oct 30, 2025 18:27 HKT
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Oct 30, 2025 16:48 HKT
云顶新耀与Visara签订协议 将在大中华区及其他亚洲市场开发及商业化VIS-101
Oct 30, 2025 16:36 HKT
雲頂新耀與Visara簽訂協議 將在大中華區及其他亞洲市場開發及商業化VIS-101
Oct 30, 2025 16:36 HKT
康哲藥業(867.HK; 8A8.SG)簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議
Oct 28, 2025 18:22 HKT
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 2025
Oct 27, 2025 21:00 HKT
Cambridge Isotope Laboratories, Inc. 在 2025 年法蘭克福國際製藥原料展(CPhI Frankfurt 2025)推出 ISOAPI-D —— 去氘試劑的新標準,推動製藥創新
Oct 27, 2025 21:00 HKT
Cambridge Isotope Laboratories, Inc. 與 Chemtatva Chiral Solutions Pvt. Ltd. 將在印度海得拉巴(Hyderabad)成立 Cambridge Isotope Laboratories, Pvt. Ltd.
Oct 27, 2025 20:45 HKT
Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India
Oct 27, 2025 20:45 HKT
康哲药业(867.HK; 8A8.SG)签订眼科药物诺适得(R)与倍优适(R)经销协议
Oct 27, 2025 18:29 HKT
云顶新耀召开公司发展战略交流会 加强全球布局 实现跨越式发展战略
Oct 22, 2025 13:53 HKT
雲頂新耀召開公司發展戰略交流會 加強全球佈局 實現跨越式發展戰略
Oct 22, 2025 13:53 HKT
Owkin 推出 K Pro:首个由生物推理模型驱动的生物制药智能 AI 协作助手
Oct 16, 2025 14:00 HKT
Owkin 推出 K Pro:首個由生物推理模型驅動的生物製藥智能 AI 協作助手
Oct 16, 2025 14:00 HKT
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT
雲頂新耀EVM14全球臨床穩步推進 中美IND「雙獲批」後美國首例患者成功入組
Oct 14, 2025 17:32 HKT
云顶新耀EVM14全球临床稳步推进 中美IND"双获批"后美国首例患者成功入组
Oct 14, 2025 17:13 HKT
康基医疗与Knight Bidco联合发布私有化建议计划文件
Oct 13, 2025 10:14 HKT
Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal
Oct 13, 2025 10:14 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: